MacKillop, James http://orcid.org/0000-0002-8695-1071
Agabio, Roberta http://orcid.org/0000-0001-7395-6845
Feldstein Ewing, Sarah W.
Heilig, Markus
Kelly, John F.
Leggio, Lorenzo
Lingford-Hughes, Anne
Palmer, Abraham A.
Parry, Charles D.
Ray, Lara
Rehm, Jürgen http://orcid.org/0000-0001-5665-0385
Article History
Accepted: 1 November 2022
First Online: 22 December 2022
Competing interests
: J.M. is a principal and senior scientist in BEAM Diagnostics, Inc. and a consultant to Clairvoyant Therapeutics, Inc.; no associated products or services are discussed in the article. Outside his federal employment, L.L. receives an honorarium from the UK Medical Council on Alcoholism (Editor-in-Chief for <i>Alcohol and Alcoholism</i>) and royalties from Routledge for a textbook. A.A.P. is on the Scientific Advisory Board of Vivid Genomics and is listed as an inventor on US patent US20160038559A1. M.H. is a member of the scientific advisory council of the Swedish Medical Products Agency, and Scientific Advisor to the Board of Health and Social Welfare; his views expressed here do not represent those of these agencies; M.H. has received consulting fees, research support or other compensation from Indivior, Camurus, Molteni, BrainsWay, Aelis Farma, Lundbeck and Janssen Pharmaceuticals. A.L.-H. has received honoraria paid into her Institutional funds for speaking and chairing engagements from Lundbeck, Lundbeck Institute UK, Janssen-Cilag, Pfizer and Servier; has received honoraria to deliver training and education for the British Association for Psychopharmacology; has received research grants or support from Lundbeck and GSK, and unrestricted funding from Alcarelle for a PhD; has been consulted by but received no monies from Dobrin; and is a member of a group producing UK Alcohol Clinical Guidelines, UK Government (Office for Health Improvement and Disparities, Department of Health and Social Care). R.A., S.W.F.E., J.F.K., C.D.P., L.R. and J.R. declare no competing interests.